10-Q: Cidara Therapeutics Reacquires CD388, Divests Rezafungin in Strategic Portfolio Shift

Cidara Therapeutics reacquired full rights to its influenza drug candidate CD388 and divested its commercial product Rezafungin to focus on its Cloudbreak platform.

Summary

• Cidara Therapeutics has reacquired all rights to CD388, a drug-Fc conjugate (DFC) for influenza, from Janssen for an upfront payment of $85 million.
• The company also sold its commercial product, REZZAYO (rezafungin), to Napp Pharmaceutical Group, resulting in a strategic shift to focus on its Cloudbreak platform.
• The sale of rezafungin is classified as discontinued operations, with a loss on disposal of $1.8 million.
• Cidara received $240 million in gross proceeds from a private placement, using $85 million for the CD388 reacquisition and the remainder for its development.
• The company initiated a Phase 2b trial for CD388 in September 2024, targeting 5,000 subjects with topline data expected in the third quarter of 2025.
• Cidara's cash and cash equivalents were $127.4 million as of September 30, 2024, expected to fund operations through mid-Q4 2025.
• The company incurred a net loss of $117.5 million for the nine months ended September 30, 2024, including $84.9 million in acquired in-process R&D expenses.
• Research and development expenses were $25 million for the nine months ended September 30, 2024, compared to $28.8 million for the same period in 2023.
• Selling, general and administrative expenses were $13.3 million for the nine months ended September 30, 2024, compared to $10.1 million for the same period in 2023.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the strategic shift and reacquisition of CD388 are positive, the significant net loss and need for additional funding create uncertainty. The company's future success is heavily dependent on the success of CD388 and the Cloudbreak platform, which are still in development.

Positives

• Reacquisition of CD388 provides full control over a promising influenza drug candidate.
• Divestiture of rezafungin allows for a focused approach on the Cloudbreak platform and reduces future costs.
• Successful private placement provides significant funding for CD388 development.
• Initiation of the Phase 2b NAVIGATE study for CD388 is a key milestone.
• The company has a cash runway through mid-Q4 2025.

Negatives

• The company incurred a significant net loss of $117.5 million for the nine months ended September 30, 2024.
• The company has a limited operating history and has experienced net losses and negative cash flows since its inception.
• The company's current financial resources may not be sufficient to support its planned operations beyond mid-Q4 2025 without securing additional financing.
• The company has a material weakness in internal control over financial reporting related to indirect taxes.

Risks

• The company's ability to execute its current business plan depends on its ability to obtain additional funding.
• The company may not be able to raise additional funding on terms acceptable to the company, or at all.
• The company's ability to achieve profitability is dependent on the successful development and commercialization of its product candidates.
• The company faces substantial competition in the pharmaceutical and biotechnology industries.
• Clinical trials for CD388 or any other product candidates may be delayed, terminated, or fail to demonstrate safety and efficacy.
• The company is dependent on third parties for the manufacture of its product candidates.
• The company may not be able to obtain required regulatory approvals for its product candidates.
• The company's product candidates may not achieve market acceptance.
• The company's stock price may be volatile.

Future Outlook

The company expects its current cash and cash equivalents to fund operations through mid-Q4 2025 and plans to continue to fund its losses from operations through cash and cash equivalents on hand, as well as through future equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements.

Management Comments

• The company believes the reacquisition of CD388 is transformational for Cidara and potentially for those who could benefit from a long-acting, universal preventative against known forms of influenza.
• The company divested rezafungin to enable it to focus its resources on its core technology.

Industry Context

The strategic shift by Cidara reflects a trend in the biotechnology industry where companies focus on core competencies and high-potential assets. The reacquisition of CD388 and divestiture of rezafungin are moves to streamline operations and focus on the Cloudbreak platform, which is a novel approach to drug development.

Comparison to Industry Standards

• The upfront payment of $85 million for CD388 is significant, but not uncommon for a Phase 2 asset in the biotech industry, especially for a drug with potential for universal influenza prevention.
• The divestiture of Rezafungin is a strategic move to focus on the Cloudbreak platform, which is a novel approach to drug development, and is similar to other companies that have divested assets to focus on core competencies.
• The $240 million private placement is a substantial capital raise, which is necessary for a company in the clinical stage of development.
• The initiation of the Phase 2b NAVIGATE study is a key milestone for CD388, and the timeline for topline data in Q3 2025 is consistent with industry standards for this stage of development.
• The company's cash runway through mid-Q4 2025 is typical for a biotech company at this stage, but the need for additional funding is a common risk.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees experienced a reduction in workforce of 20 employees.
• Customers of Rezafungin were transferred to Napp.
• Suppliers may be affected by the company's strategic shift.

Next Steps

• Continue the Phase 2b NAVIGATE study for CD388.
• Seek additional funding through equity offerings, debt financings, other third-party funding, or potential licensing or collaboration arrangements.
• Continue business development discussions for oncology DFC programs, including CBO421.
• Monitor and remediate the material weakness in internal control over financial reporting.

Key Dates

Keywords

CD388, Rezafungin, Cloudbreak platform, influenza, drug-Fc conjugate, clinical trials, private placement, biotechnology, immunotherapy, Janssen, Napp, Phase 2b, NAVIGATE study